- Home
- MDB vs TEVA Comparison
MDB vs TEVA Comparison
Compare MDB & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDB
- TEVA
- Stock Information
- Founded
- MDB 2007
- TEVA 1901
- Country
- MDB United States
- TEVA Israel
- Employees
- MDB N/A
- TEVA N/A
- Industry
- MDB Computer Software: Prepackaged Software
- TEVA Biotechnology: Pharmaceutical Preparations
- Sector
- MDB Technology
- TEVA Health Care
- Exchange
- MDB Nasdaq
- TEVA Nasdaq
- Market Cap
- MDB 20.8B
- TEVA 19.2B
- IPO Year
- MDB 2017
- TEVA N/A
- Fundamental
- Price
- MDB $252.67
- TEVA $21.20
- Analyst Decision
- MDB Buy
- TEVA Buy
- Analyst Count
- MDB 29
- TEVA 7
- Target Price
- MDB $375.18
- TEVA $21.00
- AVG Volume (30 Days)
- MDB 2.8M
- TEVA 11.3M
- Earning Date
- MDB 12-09-2024
- TEVA 01-29-2025
- Dividend Yield
- MDB N/A
- TEVA N/A
- EPS Growth
- MDB N/A
- TEVA N/A
- EPS
- MDB N/A
- TEVA N/A
- Revenue
- MDB $1,916,047,000.00
- TEVA $16,772,000,000.00
- Revenue This Year
- MDB $16.04
- TEVA $4.70
- Revenue Next Year
- MDB $18.07
- TEVA $4.47
- P/E Ratio
- MDB N/A
- TEVA N/A
- Revenue Growth
- MDB 20.79
- TEVA 9.81
- 52 Week Low
- MDB $212.74
- TEVA $10.34
- 52 Week High
- MDB $509.62
- TEVA $21.98
- Technical
- Relative Strength Index (RSI)
- MDB 33.92
- TEVA 75.06
- Support Level
- MDB $260.30
- TEVA $16.25
- Resistance Level
- MDB $370.00
- TEVA $17.72
- Average True Range (ATR)
- MDB 14.38
- TEVA 0.78
- MACD
- MDB -9.83
- TEVA 0.40
- Stochastic Oscillator
- MDB 2.94
- TEVA 86.39
About MDB MongoDB Inc.
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
About TEVA Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.